D.E. Shaw & Co’s Adaptive Biotechnologies ADPT Stock Holding History

D.E. Shaw & Co’s Portfolio ADPT Stock Details ADPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$99.2M	Buy	4,625,859 +2,660,249	+135%	+$40.8M	0.05%	455
2026 Q1	$27.3M	Buy	1,965,610 +62,925	+3%	+$1M	0.02%	962
2025 Q4	$30.9M	Buy	1,902,685 +1,164,509	+158%	+$19M	0.02%	976
2025 Q3	$11M	Buy	738,176 +129,896	+21%	+$1.58M	0.01%	1599
2025 Q2	$7.09M	Buy	+608,280	New	+$5.53M	0.01%	1756
2024 Q1	–	Sell	-41,743	Closed	-$205K	–	4299
2023 Q4	$205K	Sell	41,743 -89,526	-68%	-$408K	﹤0.01%	3876
2023 Q3	$715K	Buy	131,269 +43,321	+49%	+$286K	﹤0.01%	3263
2023 Q2	$590K	Sell	87,948 -139,781	-61%	-$1.04M	﹤0.01%	3355
2023 Q1	$2.01M	Buy	227,729 +111,547	+96%	+$983K	﹤0.01%	2695
2022 Q4	$888K	Buy	116,182 +57,498	+98%	+$447K	﹤0.01%	3530
2022 Q3	$418K	Sell	58,684 -97,500	-62%	-$918K	﹤0.01%	4136
2022 Q2	$1.26M	Buy	156,184 +23,981	+18%	+$211K	﹤0.01%	3466
2022 Q1	$1.83M	Buy	+132,203	New	+$2.08M	﹤0.01%	3386
2020 Q3	–	Sell	-19,068	Closed	-$923K	–	3783
2020 Q2	$923K	Buy	+19,068	New	+$695K	﹤0.01%	2994
2020 Q1	–	Sell	-27,456	Closed	-$821K	–	3886
2019 Q4	$821K	Buy	+27,456	New	+$788K	﹤0.01%	3116

Other funds holding ADPT

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

D.E. Shaw & Co's ADPT Position: Q2 2026 in Review

D.E. Shaw & Co increased its Adaptive Biotechnologies (ADPT) stake by 135% in Q2 2026, buying an estimated $40.8M and bringing the position to 4,625,859 shares worth $99.2M. The position accounts for 0.05% of the portfolio, ranked #455.

D.E. Shaw & Co first reported a position in ADPT in Q4 2019 and has held it in 15 quarters since. 300 funds tracked by Wall St. Rank hold ADPT as of Q2 2026.

D.E. Shaw & Co held 4,625,859 shares of Adaptive Biotechnologies worth $99.2M as of Q2 2026.
D.E. Shaw & Co bought 2,660,249 Adaptive Biotechnologies shares in Q2 2026, an estimated $40.8M.
Adaptive Biotechnologies made up 0.05% of D.E. Shaw & Co's portfolio in Q2 2026, its #455 holding.
D.E. Shaw & Co first reported a position in Adaptive Biotechnologies in Q4 2019 and has held it in 15 quarters since.
300 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.